alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 426–450 of 815 studies in Getting a diagnosis (page 18 of 33) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Getting a diagnosis” covers

Getting a diagnosis — How Alzheimer's is identified, how accurate the tests are, and how early it can be caught.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Associations between sleep quality, plasma neurofilament light, and cognition in older adults without dementia

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Translational Psychiatry 2025-05-16

The relationship between sleep quality, neurofilament light chain (NFL), and cognitive impairment, including the potential effect of plasma NFL in this association, remains unclear. 3 key findings →

Design: longitudinal study Participants: 640 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal, Bidirectional Association between Gait Speed and Cognitive Function in Community-Dwelling Older Adults without Dementia

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Journal of the American Medical Directors Association 2025-03-25

This study found a reciprocal association between gait speed and global or domain-specific cognition. 5 key findings →

Design: cohort study Participants: 511 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Assessment of cognition using surveys and neuropsychological assessment: the Health and Retirement Study and the Aging, Demographics, and Memory Study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. The journals of gerontology. Series B, Psychological sciences and social sciences 2011-07-01

Cognitive assessment appropriate for diagnosis of dementia and CIND in large population surveys could be improved with more targeted information from informants and additional cognitive tests targeting other areas of brain function. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Neurology 1992-03-01

Accurate diagnosis of vascular dementia is important for the recognition of underlying pathophysiology and the institution of appropriate therapy. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Validation of the Addenbrooke's Cognitive Examination III in frontotemporal dementia and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Dementia and geriatric cognitive disorders 2013-08-15

The results of this study provide objective validation of the ACE-III as a screening tool for cognitive deficits in FTD and AD. 2 key findings →

Participants: 33 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Office of Rare Diseases neuropathologic criteria for corticobasal degeneration

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of neuropathology and experimental neurology 2002-11-01

A working group supported by the Office of Rare Diseases of the National Institutes of Health formulated neuropathologic criteria for corticobasal degeneration (CBD) that were subsequently validated by an independent group of neuropathologists. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

✓ Peer-reviewed alzhub usefulness score 53 out of 100. JAMA 1997-10-01

Alzheimer disease is progressive and irreversible, but pharmacologic therapies for cognitive impairment and nonpharmacologic and pharmacologic treatments for the behavioral problems associated with dementia can enhance quality of life. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia

✓ Peer-reviewed alzhub usefulness score 53 out of 100. International journal of geriatric psychiatry 2004-02-01

The DemTect is short (8-10 minutes), easy to administer, and its transformed total score (maximum 18) is independent of age and education. 3 key findings →

Participants: 121 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 2003-02-01

The adverse effects of obesity and hypertension in men are independent and cumulative with respect to cognitive deficit. 1 key finding →

Participants: 551 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Geriatrics & gerontology international 2010-02-04

The Cronbach's alpha of MoCA-J as an index of internal consistency was 0.74. 1 key finding →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of neurology, neurosurgery, and psychiatry 2010-10-22

Frontotemporal dementia (FTD) is the second most common young-onset dementia and is clinically characterised by progressive behavioural change, executive dysfunction and language difficulties. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Neurology 1982-02-01

To examine the possibility that senile dementia may be associated with a loss of noradrenergic neurons that innervate the cerebral cortex, we used a Quantimet 720 image analyzer to estimate the number of neurons in the nucleus locus ceruleus in elderly patients with the clinical diagnosis of senile dementia. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease?

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of neurology, neurosurgery, and psychiatry 2000-08-01

Factor analysis showed four robust and meaningful symptom clusters: factor 1-stereotypic and eating behaviour; factor 2-executive dysfunction and self care; factor 3-mood changes; factor 4-loss of social awareness. 4 key findings →

Participants: 33 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

REM sleep behaviour disorder

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Nature reviews. Disease primers 2018-08-30

Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia that is characterized by loss of muscle atonia during REM sleep (known as REM sleep without atonia, or RSWA) and abnormal behaviours occurring during REM sleep, often as dream enactments that can cause injury. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Neurology 1996-03-01

We determined whether a battery of neuropsychological tests could predict who would develop Alzheimer's disease (AD) in a group of 123 memory-impaired nondemented patients. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Acta neuropathologica 2016-04-09

Vascular dementia (VaD) is recognised as a neurocognitive disorder, which is explained by numerous vascular causes in the general absence of other pathologies. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Locus-specific mutation databases for neurodegenerative brain diseases

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Human mutation 2012-07-02

The Alzheimer disease and frontotemporal dementia (AD&FTLD) and Parkinson disease (PD) Mutation Databases make available curated information of sequence variations in genes causing Mendelian forms of the most common neurodegenerative brain disease AD, frontotemporal lobar degeneration (FTLD), and PD. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed